Press releases

Meeting of Pharmaleads Clinical Advisory Board Confirms Clinical Development Plans for PL265 and PL37

Pharmaleads Clinical Advisory Board met on November 21 2017 in Paris to discuss the future clinical development of its two Dual ENKephalinase inhibitors (DENKIs). The CAB comprises world-renowned pain specialists; Professor Nadine Attal and Dr. Didier Bouhassira from Ambroise Paré Hospital in Paris, Professor Andrew Rice from Imperial College in London and Dr. Dinesh Selvarajah […] Read full post »

Pharmaleads CEO to Present at Bio-Europe 2017

Pharmaleads, an emerging pharmaceutical company developing innovative non-opiate products for the management of acute and chronic severe pain, announces that CEO Thierry Bourbié will present a company and pipeline overview at Bio-Europe 2017 in Berlin. His presentation will take place on Tuesday 7th November at 5:45pm CET in the ‘Pain Management’ Track. Thierry Bourbié, CEO of Pharmaleads, said, “We are delighted […] Read full post »

Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor (DENKI), at the ARVO 2017 Annual Meeting

Pharmacology research conducted in conjunction with The Vision Institute, Paris  Paris, France, 12th May 2017 – Pharmaleads, an emerging pharmaceutical company developing innovative products for the management of acute and chronic severe pain, today announced positive efficacy and safety results of PL265, a novel Dual ENKephalinase Inhibitor (DENKI),  in a preclinical study for ocular pain. […] Read full post »

Older posts

Page 2 of 212
Discover our publications
NEWS RELEASES